Scientific Evidence

Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder

May 2023

In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test

Author: Cao F, Maciel A, Wosnik K, et al.

Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting

Incorporation of the 40-gene expression profile (40-GEP) test to improve treatment decisions in high-risk cutaneous squamous cell carcinoma (cSCC) patients: case series and algorithm

May 2023

Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes. 

Author: Singh G, et al.

Publication: Clinical, Cosmetic and Investigational Dermatology

A tissue systems pathology test enables risk-aligned management of patients with non-dysplastic Barrett’s esophagus: a case series at an expert foregut surgery center

May 2023

Author: Wisniowski P, et al.

Publication: Podium presentation (643) at DDW 2023, Chicago

A tissue systems pathology test outperforms standard clinicopathic variables in predicting progression in patients with Barrett’s esophagus

May 2023

Author: Davison JM, et al.

Publication: Podium presentation (222) at DDW 2023, Chicago

A tissue systems pathology test enables standardized, risk-aligned management of patients with Barrett’s esophagus

May 2023

Author: Duits LC, et al.

Publication: Poster presentation (Tu1271) at DDW 2023, Chicago

A tissue systems pathology test objectively risk-stratifies patients with Barrett's esophagus: results from a multicenter U.S. clinical experience

May 2023

Author: Villa NA, et al.

Publication: Poster presentation (Tu1272) at DDW 2023, Chicago

A tissue systems pathology test has significant clinical utility to standardize management leading to improved health outcomes for Barrett’s esophagus patients with low-grade dysplasia

May 2023

Author: Khoshiwal AM, et al.

Publication: Poster presentation (Tu1270) at DDW 2023, Chicago

Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies

Mar 2023

Independent mulit-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

Author: Dhillon S, et al.

Publication: Archives of Derm Research

Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis

Mar 2023

Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.

Author: Bunka M, et al.

Publication: Psychiatry Res

The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study

Jan 2023

DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.

Author: Yamamoto M, et al.

Publication: Current Medical Research and Opinion

Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel report

Jan 2023

Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing.

Author: Zakria D, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma

Jan 2023

Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.

Author: Martin B, et al.

Publication: Poster, presented at Winter Clinical Dermatolog conference- Hawaii Jan 13-18 2023